ArticleScientific reports2026
Polyclonal antibodies and probiotics improve immune dysfunction in a mouse model of inflammatory bowel disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic digestive disorder caused by the overactivity of the mucosal immune system in response to natural intestinal bacteria and environmental factors, affecting genetically susceptible individuals. This research investigates the preventive effect of probiotics (P), specifically Lactobacillus fermentum, Lactobacillus L. reuteri, and polyclonal antibodies (AB), on morphological changes and markers of intestinal inflammation in the IBD mice model. Our study spanned 54 days. For the first 21 days, we observed microbial populations and immunoglobulin levels. Then, we induced chronic inflammation over three 11-day cycles. In each cycle, subjects received 2% dextran sulfate sodium (DSS) for 4 days, followed by 7 days of normal water. 75 C57BL/6 mice have been used in 5 groups: DSS, control, DSS + P, DSS + AB, and a combined treatment group of antibodies and probiotics (DSS + ABP). Throughout the study period, clinical symptoms were monitored, and morphological changes and histological scores were assessed after the course. Levels of IBD biomarkers in serum such as nitrite, malondialdehyde enzyme (MDA), and myeloperoxidase enzyme (MPO), were measured along with alterations in cytokines Tumor Necrosis Factor-alpha (TNF-α), interleukin (IL)-4, IL-6, and IL-22, IgA and IgG in the blood serum. Results showed that All treatment groups, significantly reduced the Disease Activity Index (DAI), total histological score and oxidative stress markers MDA and MPO compared to the DSS group (p < 0.05). Additionally, the oral administration of polyclonal antibodies increased mucosal immunoglobulin levels, helping to prevent the rise in serum immunoglobulin levels and the associated increase in IL-4 (p < 0.05). Meanwhile, treatment with probiotics significantly (p < 0.05) reduced inflammation by modulating cytokine levels (TNF-α and IL-6). In conclusion, the co-administration of probiotics and polyclonal antibodies effectively mitigates IBD progression by synergistically improving histological parameters and regulating systemic immune responses, offering a more potent preventive strategy than individual treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.